Steve Egwuonwu, MD
Internal Medicine · Lawton, OKNPI 1053519587
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $463,485 of the $463,823 with a category attached, or 99.9%. CSL Behring accounts for 99.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $136,723 and has fallen 100.0% since, to $62 in 2025. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $1332.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$463K
- AstraZeneca$91
- GSK$46
- Siemens Medical Solutions USA, Inc.$46
- Amarin Pharma, Inc.$25
- Ultragenyx Pharmaceutical Inc.$20
- plus $109 from 7 others
What the payments were for
- Consulting fees$463,485100%
- Food & beverage$3110%
- Entertainment$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 329 | $463,485 |
| AstraZeneca | 5 | $91 |
| GSK | 3 | $46 |
| Siemens Medical Solutions USA, Inc. | 2 | $46 |
| Amarin Pharma, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Abbott | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| AbbVie | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
How this compares
$463,823 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 46 | $57,739 |
| JardianceEmpagliflozin | 15 | $24,273 |
| EliquisApixaban | 37 | $19,370 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $18,727 |
| JanuviaSitagliptin Phosphate | 14 | $13,573 |
| FarxigaDapagliflozin Propanediol | 14 | $10,417 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,160 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,692 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,467 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,809 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,766 |
| Ventolin HfaAlbuterol Sulfate | 47 | $3,264 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,255 |
| Gabapentin | 150 | $2,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $19 | $57,73946 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $46 | $25,41934 claims |
| AstraZenecaFarxiga, Symbicort | $91 | $16,22637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Lawton
- Jesse RichardsTulsa$279K
- Ryan MorganOklahoma City$235K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Ali JafryOklahoma City$33K
- Gerard McNultyTulsa$27K
- Yasir UsmanEnid$27K
- Peter LantzTulsa$23K
- Sudip TripathyTulsa$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.